Academic Office:
Louisiana Cancer Research Center
1700 Tulane Ave
New Orleans, LA 70112
Bio
Shou-Ching Tang, MD, PhD, FACP, FRCPC, is a world-renowned clinician scientist and cancer center administrator with a passion for cancer clinical and translational research and breast cancer prevention, diagnosis, and treatment. He is certified in medical oncology by the American Board of Internal Medicine and the Royal College of Physicians and Surgeons of Canada. He currently serves as Associate Dean of Translational Research and Tenured Professor at the LSU Health New Orleans School of Medicine, Associate Director for Clinical Research at the Louisiana Cancer Research Center, and Director of the Phase I Clinical Trials Program.
As Associate Director for Clinical Research, Dr. Tang is responsible for organizing research programs in clinical research that foster collaboration, innovation, and impact, and engaging members and facilitating careers in clinical cancer research. In addition, Dr. Tang is working with junior clinical faculty as part of a mentoring program.
As the Associate Dean for Translational Research, Dr. Tang provides leadership and strategic direction on the clinical and translational research efforts across the LSU Health New Orleans School of Medicine.
Education
Doctorate:
Ph.D.
Molecular Biology
University of Alberta
Edmonton, Alberta, Canada
Medical:
M.D.
West China University of Medical Sciences
Chengdu, Sichuan, China
Fellowship:
Medical Oncology
Princess Margaret Hospital
Toronto, Ontario, Canada
Publications
1. Smeijer JD, Kohan DE, Rossing P, Correa-Rotter R, Liew A, Tang SCW, de Zeeuw D, Gansevoort RT, Ju W, Lambers Heerspink HJ. Insulin resistance, kidney outcomes and effects of the endothelin receptor antagonist atrasentan in patients with type 2 diabetes and chronic kidney disease. Cardiovasc Diabetol. 2023 Sep 16;22(1):251. doi: 10.1186/s12933-023-01964-8. PMID: 37716952; PMCID: PMC10505320.
2. Xiao G, Li X, Li G, Zhang B, Xu C, Qin S, Du N, Wang J, Tang SC, Zhang J, Ren H, Chen K, Sun X. Correction: MiR-129 blocks estrogen induction of NOTCH signaling activity in breast cancer stem-like cells. Oncotarget. 2023 Sep 15;14:809. doi: 10.18632/oncotarget.28201. Erratum for: Oncotarget. 8:103261. PMID: 37713331; PMCID: PMC10503734.
3. Hsin IL, Wu PJ, Tang SC, Ou CC, Chang HY, Shen HP, Ko JL, Wang PH. β-catenin inhibitor ICG-001 suppress cell cycle progression and induce autophagy in endometrial cancer cells. J Cell Physiol. 2023 Sep 8. doi: 10.1002/jcp.31103. Epub ahead of print. PMID: 37682852.
4. Liao ZX, Hsu SH, Tang SC, Kempson I, Yang PC, Tseng SJ. Potential targeting of the tumor microenvironment to improve cancer virotherapy. Pharmacol Ther. 2023 Aug 30;250:108521. doi: 10.1016/j.pharmthera.2023.108521. Epub ahead of print. PMID: 37657673.
5. Chan KW, Smeijer JD, Schechter M, Jongs N, Vart P, Kohan DE, Gansevoort RT, Liew A, Tang SCW, Wanner C, de Zeeuw D, Heerspink HJL. Post hoc analysis of the SONAR trial indicates that the endothelin receptor antagonist atrasentan is associated with less pain in patients with type 2 diabetes and chronic kidney disease. Kidney Int. 2023 Aug 31:S0085-2538(23)00610-5. doi: 10.1016/j.kint.2023.08.014. Epub ahead of print. PMID: 37657768.
6. Zhang R, Chen CH, Tezenas Du Montcel S, Lebenberg J, Cheng YW, Dichgans M, Tang SC, Chabriat H. The CADA-MRIT: An MRI Inventory Tool for Evaluating Cerebral Lesions in CADASIL Across Cohorts. Neurology. 2023 Aug 31:10.1212/WNL.0000000000207713. doi: 10.1212/WNL.0000000000207713. Epub ahead of print. PMID: 37652700.
7. Chen SJ, Tsai HH, Lo YL, Chen YF, Tang SC, Jeng JS, Tsai LK. Interaction between cerebral small vessel disease, blood pressure, and remote ischemic lesions in acute spontaneous intracerebral hemorrhage. Eur Stroke J. 2023 Sep;8(3):828-835. doi: 10.1177/23969873231170989. Epub 2023 Apr 20. PMID: 37641548; PMCID: PMC10472944.
8. Lin HJ, Chen CH, Su MW, Lin CW, Cheng YW, Tang SC, Jeng JS. Modifiable vascular risk factors contribute to stroke in 1080 NOTCH3 R544C carriers in Taiwan Biobank. Int J Stroke. 2023 Aug 11:17474930231191991. doi: 10.1177/17474930231191991. Epub ahead of print. PMID: 37485895.
9. Li K, Peng ZY, Wang R, Li X, Du N, Liu DP, Zhang J, Zhang YF, Ma L, Sun Y, Tang SC, Ren H, Yang YP, Sun X. Enhancement of TKI sensitivity in lung adenocarcinoma through m6A-dependent translational repression of Wnt signaling by circ-FBXW7. Mol Cancer. 2023 Jul 1;22(1):103. doi: 10.1186/s12943-023-01811-0. PMID: 37393311; PMCID: PMC10314519.
10. Yeh SJ, Chen CH, Lin YH, Tsai LK, Lee CW, Tang SC, Jeng JS. Association of Ferroptosis with Severity and Outcomes in Acute Ischemic Stroke Patients Undergoing Endovascular Thrombectomy: A Case-control Study. Mol Neurobiol. 2023 Oct;60(10):5902-5914. doi: 10.1007/s12035-023-03448-y. Epub 2023 Jun 26. PMID: 37357230.
Research
Title: Determining the contribution of TPR to platelet-mediated cancer metastasis
Sponsor: American Cancer Society grant # RSG-21-114-01-MM
Role: Collaborator (Werfel T)
Dates: 01/01/22-12/31/26
Title: Investigating Platinum(IV) Compounds with Novel Properties Against Chemotherapy Resistance
and Lipogenesis in In Vitro and In Vivo Ovarian Cancer Models
Sponsor: Department of Defense (DOD) ovarian cancer breakthrough award level 1
Role: Co-investigator (Gilbert A)
Dates: 01/01/2022-12/31/2023
Title: HER2-Targeting Chimeric Antigen Receptor Myeloid Cells Derived from Expanded Cord
Blood Hematopoietic Stem and Progenitor Cells for Ovarian Cancer Immunotherapy
Sponsor: Department of Defense (DOD) Congressionally Directed Medical Research Programs (CDMRP)
Role: Collaborator (Cotari J)
Dates: 01/01/2023-12/31/2024
Dr. Tang was very productive in basic research in the molecular characterization and clinical application of anti-apoptotic protein BAG-1, use of BAG-1 as a clinical prognostic factor in solid tumors and the development of novel targeted therapy. His lab independently cloned BAG-1, a molecular chaperone and transcription factor for steroids superfamily proteins, including ER/PR. He was the first to observe the overexpression of BAG-1 in human malignancies and discovered the functions and prognostic value of BAG-1 isoforms in breast and lung cancers. BAG-1 is now part of the 16 genes used in Oncotype DX test. He was also the first to report the role played by BAG-1 in resistance to tamoxifen, taxol and anthracyclines. He cloned the transcription factor of BAG-1 as well. The monoclonal antibodies against BAG-1 he raised are licensed to Santa Cruz Biotechnology. His research work has been funded through several MRC/CIHR/NCIC operating grants from Canada (R01 equivalent).
His primary contributions in clinical cancer research include clinical trials in breast cancer and lung cancers. He was the founding Chair of the Atlantic Canada Oncology Group (ACOG), Founding Member and Scientific Advisor for the Breast Cancer International Research Group (BCIRG). He was the Founding Member of the Breast Cancer International Research Group (BCIRG) and served on its Scientific Advisory Board. He was also a member of the ECOG Thoracic Core Committee and Biotherapy Sub-Committee. He was the Principle Investigator on many landmark clinical trials with publications in Lancet and the NEJM. Dr. Tang founded the Asia International Breast Cancer Summit (AIBCS) and has chaired its annual meeting in Asia many times. He is the Founding President of the US Chinese Anticancer Association (USCACA) as well.
He has been interested in the study of prognostic and predictive biomarkers in cancer over the past 20 years. He is also interested in clinical trials of novel and targeted therapies in breast and lung cancers. His recent research efforts are focused on precision medicine and immunotherapy.